--- title: "Neoadjuvant Gynecological Cancers CORT125134-557 BELLA | Sutter Health" description: "An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)" url: "https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gynecological-cancers-cort125134-557-bella-2072220354" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Neoadjuvant Gynecological Cancers CORT125134-557 BELLA # Neoadjuvant Gynecological Cancers CORT125134-557 BELLA **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gynecological-cancers-cort125134-557-bella-2072220354#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06906341). #### Locations - San Francisco #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA) ![John K Chan, M.D.](https://dyn.mktgcdn.com/p/pjEBXftGFCdPi0LQIN6WcSp3QpqbnJX3LiI6Cwd3g4w/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) John K Chan, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/john-k-chan-md-1049681255) ## Sub-Investigator [Lejla Delic, M.D.](https://www.sutterhealth.org/research/investigators/lejla-delic-md-1049681192) ## Email us to enroll - [Email San Francisco](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Neoadjuvant%20Gynecological%20Cancers%20CORT125134-557%20BELLA%20in%20San%20Francisco&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Advanced Solid Tumors RAINFOL-01](https://www.sutterhealth.org/research/clinical-trials/advanced-solid-tumors-rainfol-01-2023025237) Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Advance Ovarian Cancer FRAmework-01 J5E-MC-JZXB](https://www.sutterhealth.org/research/clinical-trials/adjuvant-advance-ovarian-cancer-framework-01-j5e-mc-jzxb-2066913418) FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer. **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Endometrial Cancer GCT1184-03](https://www.sutterhealth.org/research/clinical-trials/adjuvant-endometrial-cancer-gct1184-03-2064306931) A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Endometrial Cancer NRG GY032](https://www.sutterhealth.org/research/clinical-trials/adjuvant-endometrial-cancer-nrg-gy032-2020963897) A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER) **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Ovarian Cancer NRG-GY036](https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-nrg-gy036-2015844362) A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gynecological-cancers-cort125134-557-bella-2072220354#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Neoadjuvant Gynecological Cancers CORT125134-557 BELLA"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gynecological-cancers-cort125134-557-bella-2072220354#medicalwebpage","name":"Neoadjuvant Gynecological Cancers CORT125134-557 BELLA","description":"An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)","url":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gynecological-cancers-cort125134-557-bella-2072220354","inLanguage":"en-US","dateModified":"2026-07-06","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gynecological-cancers-cort125134-557-bella-2072220354#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gynecological-cancers-cort125134-557-bella-2072220354#breadcrumblist"},"mentions":[{"@type":"Person","name":"John K Chan, M.D.","url":"https://www.sutterhealth.org/research/investigators/john-k-chan-md-1049681255","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gynecological-cancers-cort125134-557-bella-2072220354#medicaltrial","name":"Neoadjuvant Gynecological Cancers CORT125134-557 BELLA","alternateName":"An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)","url":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gynecological-cancers-cort125134-557-bella-2072220354","description":"An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)","identifier":"NCT06906341","code":{"@type":"MedicalCode","codeValue":"NCT06906341","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT06906341","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Ovarian Cancer"},{"@type":"MedicalCondition","name":"Endometrial Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"San Francisco"}]} ```